HPA Axis Explained: Hypothalamus-Pituitary-Adrenal in Stress

Adrenal disorders include Cushing's syndrome (excess cortisol) and Addison's disease (adrenal insufficiency). Cushing's presents with central obesity, moon face, and hypertension. Addison's causes fatigue, hypotension, and hyperpigmentation. Addisonian crisis is a life-threatening emergency requiring IV hydrocortisone and fluid replacement. Diagnosis involves cortisol measurements and ACTH stimulation testing.

Dysregulation of cortisol production produces clinically distinct syndromes. Cushing's syndrome results from chronic cortisol excess (adrenal or pituitary tumors), manifesting as central obesity with full moon face, buffalo hump, striae, hypertension, hypokalemia, osteoporosis, acne, and immunosuppression. Addison's disease (primary adrenal insufficiency) represents cortisol deficiency, presenting with hypoglycemia, hypotension, hyponatremia, hyperkalemia, weight loss, fatigue, and characteristic hyperpigmentation due to compensatory ACTH-induced melanin stimulation. These conditions demonstrate the critical role of cortisol in maintaining homeostasis across metabolic, immune, cardiovascular, and neurological systems.

Adrenal gland disorders result from hormone imbalances. Addison's disease (hormone deficiency) causes low blood sugar, persistent vomiting, weight loss, and reduced cognitive function. Cushing's syndrome (hormone excess) causes excessive fat accumulation, particularly in the face (moon face), and sunken eyes. These conditions result from improper regulation of adrenal hormones and represent the two main disorders of the adrenal glands.

Cushing's syndrome results from excessive cortisol exposure (either from pituitary tumors causing ACTH overproduction or from glucocorticoid drug therapy). Symptoms include moon face, buffalo hump, hypertension, hyperglycemia, and immunosuppression. Addison's disease results from adrenal insufficiency, causing fatigue, weight loss, hypotension, hyperpigmentation, and salt cravings.

Cushing's syndrome presents with characteristic signs: fragile skin bruising easily, trunkal obesity with thin extremities, moon face, reproductive dysfunction, hypertension, purple striae, hyperglycemia, hirsutism, buffalo hump, and depression. Addison's disease shows opposite patterns: hyponatremia/hypoglycemia, salt cravings, fatigue/muscle weakness, electrolyte imbalances (hyperkalemia), reproductive changes, hypotension, hyperpigmentation, and GI symptoms. These contrasting presentations reflect excessive versus deficient cortisol and aldosterone activity, demonstrating how hormone levels directly determine clinical outcomes.

Exogenous glucocorticoids like prednisone structurally mimic cortisol and exert powerful negative feedback on the HPA axis. This suppression occurs at two levels: the hypothalamus decreases CRH release, and the anterior pituitary reduces ACTH secretion. Consequently, POMC synthesis decreases, leading to reduced ACTH and alpha-MSH production. Despite elevated exogenous steroid levels, the body's own cortisol production drops significantly. This explains why patients on long-term steroids have suppressed ACTH and cortisol levels despite clinical manifestations of Cushing syndrome. The key principle is that exogenous glucocorticoids are not identical to endogenous cortisol—they act as pharmacological antagonists of the HPA axis, making them fundamentally different from endogenous hypercortisolism.

This section covers synthetic glucocorticoids and their clinical applications. Synthetic glucocorticoids (prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone) are designed to have enhanced properties: increased receptor affinity for longer duration, increased binding to corticosteroid-binding globulin (CBG) for prolonged circulation, reduced metabolic clearance, and reduced metabolite production. Prednisone is preferred in pregnancy because it's a prodrug that must be converted to prednisolone by hepatic enzymes; the placenta prevents prednisolone from crossing to the fetus, protecting the baby while the mother receives therapeutic benefit. Glucocorticoids vary in potency: hydrocortisone (baseline), prednisone (4x), methylprednisolone (5x), triamcinolone (25x), and dexamethasone (30x). Long-acting agents include prednisone, dexamethasone, and methylprednisolone. Long-term high-dose therapy causes adrenal suppression: exogenous glucocorticoids provide negative feedback, suppressing ACTH and CRH production, causing adrenal cortex atrophy. To prevent this, alternate-day therapy is used - giving glucocorticoids every other day to allow the adrenal gland to function normally on treatment-free days.

Glucocorticoid therapy indications include endocrine (adrenal insufficiency, replacement therapy) and non-endocrine uses (anti-inflammatory for arthritis, ulcerative colitis, nephrotic syndrome; immunosuppressive for autoimmune diseases, transplants; anti-allergy for asthma). Synthetic glucocorticoids differ from cortisol in pharmacokinetics and pharmacodynamics, administered orally, IV, topically, rectally, or via inhalation. Potency is measured relative to hydrocortisone: prednisone (5mg), methylprednisone (4mg), dexamethasone (750mcg), betamethasone (750mcg). Duration varies: short-acting (hydrocortisone for emergencies), intermediate-acting (prednisone), long-acting (dexamethasone, betamethasone).

The hypothalamic-pituitary-adrenal (HPA) axis regulates cortisol through a negative feedback loop: the hypothalamus releases CRH stimulating the pituitary to release ACTH, which then stimulates cortisol production. Cortisol exerts negative feedback on both the hypothalamus and pituitary to maintain normal levels. However, extended use of exogenous glucocorticoids like prednisone mimics cortisol's effects, suppressing CRH and ACTH release. This causes the adrenal glands to atrophy and stop producing cortisol naturally. Patients become dependent on external steroids, and sudden discontinuation can lead to life-threatening adrenal crisis, requiring gradual tapering to restore natural production.

Synthetic glucocorticoids are steroid hormones that mimic cortisol's anti-inflammatory and metabolic effects by binding to cytoplasmic receptors, entering the nucleus, and binding to glucocorticoid response elements to regulate gene transcription. They are classified by duration of action: hydrocortisone (short-acting, chemically identical to cortisol), prednisone/prednisolone/methylprednisolone (intermediate-acting, 4-5 times more potent), and dexamethasone (long-acting, highly potent with pituitary-adrenal axis suppression). These medications are used for hormone replacement in adrenal insufficiency and as anti-inflammatory/immunosuppressive agents for conditions like rheumatoid arthritis, asthma, and autoimmune diseases. The dexamethasone suppression test uses these drugs to diagnose Cushing's syndrome, while iatrogenic Cushing's syndrome represents the common side effect profile including buffalo hump, moon face, hypertension, osteoporosis, hyperglycemia, and increased infection risk.

The HPA axis is a complex neuroendocrine system that regulates stress responses. When stressors trigger afferent signals through the nervous system, the hypothalamus releases hormones that stimulate the anterior pituitary to release ACTH. ACTH then travels through the bloodstream to the adrenal cortex, stimulating the release of multiple hormones including mineralocorticoids, glucocorticoids, and androgens. This cascade represents the body's primary mechanism for responding to stress.

The HPA axis is the body's stress response pathway: the hypothalamus releases CRH (corticotropin-releasing hormone), which signals the pituitary gland to release ACTH (adrenocorticotropic hormone), which then stimulates the adrenal cortex to release cortisol. This axis coordinates the body's response to stress.

Neuroendocrine reflexes coordinate glandular responses to sensory inputs. For example, suckling stimulates oxytocin release, triggering milk letdown. Osmoreceptors in the hypothalamus detect blood solute concentration and trigger ADH release for water balance. The circadian rhythm (body clock) is regulated by light input through the retina to the hypothalamus, controlling melatonin and cortisol secretion patterns that govern daily physiological cycles.

The HPA axis (Hypothalamus-Pituitary-Adrenal axis) is the regulatory system that controls cortisol production. The hypothalamus releases CRH (corticotropin-releasing hormone), which stimulates the pituitary gland to release ACTH (adrenocorticotropic hormone). ACTH then travels through the bloodstream to the adrenal glands, stimulating them to produce and release cortisol. This axis is activated during stress situations.

The hypothalamic-pituitary-gonadal axis controls reproductive function: (1) Hypothalamus releases GnRH (gonadotropin-releasing hormone), (2) Pituitary gland releases LH (luteinizing hormone) and FSH (follicle-stimulating hormone), (3) LH stimulates Leydig cells to produce testosterone, (4) FSH stimulates Sertoli cells to support sperm development. This axis is activated during puberty. Testosterone is a steroid hormone (lipid-based) that acts on target tissues. It stimulates: (1) Development of male secondary sexual characteristics, (2) Sperm production in seminiferous tubules, (3) Muscle and bone development.